Lyell Immunopharma, Inc. (LYEL) Stock

Lyell Immunopharma, Inc. (LYEL) is a Healthcare stock trading at $12.64 (as of 2026-06-18), with a market capitalization of $404.38M and a trailing P/E of -0.8. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Lyell Immunopharma, Inc. develops ex vivo T cell therapies for patients with solid tumors using genetic and epigenetic reprogramming platforms, including Gen-R and Epi-R. Its pipeline includes T cell product candidates LYL797 and LYL845, and NY-ESO-1, with a research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1.

Valuation — source: SEC EDGAR (first-party)
Price	$12.64
Market Cap	$404.38M
P/E Ratio	-0.8
EV / EBITDA	-0.8
Price / Book	1.09
Price / Sales	9589.56
DCF Value (model)	$-107.50
DCF Upside vs Price	-950.1%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$36000.00
Net Margin	-762355.6%
Return on Equity	-90.0%
Current Ratio	7.23
Revenue Growth (YoY)	-71.4%
EPS Growth (YoY)	511.1%
FCF Growth (YoY)	-29.8%

Financial Health — source: SEC EDGAR
Altman Z-Score	-6.61 (distress)

Valuation vs Sector & Industry
Stock P/E	-0.8
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-103.6%
vs Industry	-104.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	ARCH Venture Management, LLC ($65.14M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Lynn Seely
Employees	300
Country	US
IPO Date	2021-06-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.